An individual participant data meta-analysis of 18 fixed-dose trials involving 7062 adults with acute schizophrenia found no evidence of sex differences in antipsychotic efficacy for overall symptom improvement.
An individual participant data meta-analysis of 18 fixed-dose trials involving 7062 adults with acute schizophrenia found no evidence of sex differences in antipsychotic efficacy for overall symptom improvement.
The US Food and Drug Administration (FDA) granted 510(k) clearance for Motivista, the first treatment specifically authorized for negative symptoms of schizophrenia in adults.
The US Food and Drug Administration (FDA) granted 510(k) clearance for Motivista, the first treatment specifically authorized for negative symptoms of schizophrenia in adults.
Young people beginning antipsychotic treatment after first-episode psychosis had low medication adherence, according to a retrospective US cohort study published in JAMA Network Open.
Young people beginning antipsychotic treatment after first-episode psychosis had low medication adherence, according to a retrospective US cohort study published in JAMA Network Open.
Once-monthly aripiprazole 400 mg (AOM 400) demonstrated a favorable risk-benefit profile as an acute and long-term maintenance treatment in patients with schizophrenia.
Once-monthly aripiprazole 400 mg (AOM 400) demonstrated a favorable risk-benefit profile as an acute and long-term maintenance treatment in patients with schizophrenia.
The US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for lumateperone (CAPLYTA) for relapse prevention in schizophrenia.
The US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for lumateperone (CAPLYTA) for relapse prevention in schizophrenia.
Interim results from a phase 2 randomized, double-blind, placebo-controlled trial of tazbentetol demonstrated early signals of efficacy across schizophrenia symptom domains.
Interim results from a phase 2 randomized, double-blind, placebo-controlled trial of tazbentetol demonstrated early signals of efficacy across schizophrenia symptom domains.
A research letter published in JAMA Psychiatry reports that reduced grip strength may represent a transdiagnostic marker across schizophrenia and depression, including remitted depression.
A research letter published in JAMA Psychiatry reports that reduced grip strength may represent a transdiagnostic marker across schizophrenia and depression, including remitted depression.
Clozapine was more effective than olanzapine and amisulpride in first-episode psychosis (FEP) patients with schizophrenia, schizophreniform, or schizoaffective disorder who did not respond to an initial antipsychotic.
Clozapine was more effective than olanzapine and amisulpride in first-episode psychosis (FEP) patients with schizophrenia, schizophreniform, or schizoaffective disorder who did not respond to an initial antipsychotic.
The integration of physical activity into routine psychiatric care could significantly improve outcomes for people with severe mental illness (SMI), including schizophrenia, according to a narrative review published in JAMA Psychiatry.
The integration of physical activity into routine psychiatric care could significantly improve outcomes for people with severe mental illness (SMI), including schizophrenia, according to a narrative review published in JAMA Psychiatry.
Increased copy number variant (CNV) burden, specifically deletions, is associated with earlier age at onset (AAO) of schizophrenia, according to recent research findings.
Increased copy number variant (CNV) burden, specifically deletions, is associated with earlier age at onset (AAO) of schizophrenia, according to recent research findings.
An individual participant data meta-analysis of 18 fixed-dose trials involving 7062 adults with acute schizophrenia found no evidence of sex differences in antipsychotic efficacy for overall symptom improvement.
An individual participant data meta-analysis of 18 fixed-dose trials involving 7062 adults with acute schizophrenia found no evidence of sex differences in antipsychotic efficacy for overall symptom improvement.
Young people beginning antipsychotic treatment after first-episode psychosis had low medication adherence, according to a retrospective US cohort study published in JAMA Network Open.
Young people beginning antipsychotic treatment after first-episode psychosis had low medication adherence, according to a retrospective US cohort study published in JAMA Network Open.
Once-monthly aripiprazole 400 mg (AOM 400) demonstrated a favorable risk-benefit profile as an acute and long-term maintenance treatment in patients with schizophrenia.
Once-monthly aripiprazole 400 mg (AOM 400) demonstrated a favorable risk-benefit profile as an acute and long-term maintenance treatment in patients with schizophrenia.
Interim results from a phase 2 randomized, double-blind, placebo-controlled trial of tazbentetol demonstrated early signals of efficacy across schizophrenia symptom domains.
Interim results from a phase 2 randomized, double-blind, placebo-controlled trial of tazbentetol demonstrated early signals of efficacy across schizophrenia symptom domains.
A research letter published in JAMA Psychiatry reports that reduced grip strength may represent a transdiagnostic marker across schizophrenia and depression, including remitted depression.
A research letter published in JAMA Psychiatry reports that reduced grip strength may represent a transdiagnostic marker across schizophrenia and depression, including remitted depression.
Clozapine was more effective than olanzapine and amisulpride in first-episode psychosis (FEP) patients with schizophrenia, schizophreniform, or schizoaffective disorder who did not respond to an initial antipsychotic.
Clozapine was more effective than olanzapine and amisulpride in first-episode psychosis (FEP) patients with schizophrenia, schizophreniform, or schizoaffective disorder who did not respond to an initial antipsychotic.
The integration of physical activity into routine psychiatric care could significantly improve outcomes for people with severe mental illness (SMI), including schizophrenia, according to a narrative review published in JAMA Psychiatry.
The integration of physical activity into routine psychiatric care could significantly improve outcomes for people with severe mental illness (SMI), including schizophrenia, according to a narrative review published in JAMA Psychiatry.
Increased copy number variant (CNV) burden, specifically deletions, is associated with earlier age at onset (AAO) of schizophrenia, according to recent research findings.
Increased copy number variant (CNV) burden, specifically deletions, is associated with earlier age at onset (AAO) of schizophrenia, according to recent research findings.
A comprehensive economic evaluation reported substantial national and state-level societal costs of schizophrenia in the United States for the 2024 calendar year, estimating a total excess societal cost at $366.8 billion.
A comprehensive economic evaluation reported substantial national and state-level societal costs of schizophrenia in the United States for the 2024 calendar year, estimating a total excess societal cost at $366.8 billion.
The FDA has approved milsaperidone for the treatment of schizophrenia in adults and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.
The FDA has approved milsaperidone for the treatment of schizophrenia in adults and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.
A self-led digital intervention targeting repetitive negative thinking significantly reduced anxiety during pregnancy and after childbirth, according to recent findings.
A self-led digital intervention targeting repetitive negative thinking significantly reduced anxiety during pregnancy and after childbirth, according to recent findings.
A single administration of mebufotenin benzoate nasal spray produced rapid, sustained reductions in depressive symptoms among adults with TRD, according to a phase 2b trial published in JAMA.
A single administration of mebufotenin benzoate nasal spray produced rapid, sustained reductions in depressive symptoms among adults with TRD, according to a phase 2b trial published in JAMA.
Investigational RAP-219 met the primary and secondary endpoints in a randomized, double-blind, placebo-controlled trial of adults experiencing acute bipolar mania, manufacturer Rapport Therapeutics announced on October 20, 2026.
Investigational RAP-219 met the primary and secondary endpoints in a randomized, double-blind, placebo-controlled trial of adults experiencing acute bipolar mania, manufacturer Rapport Therapeutics announced on October 20, 2026.
Home transcranial direct current stimulation paired with cognitive training delivered through a video game was feasible but offered no superior antidepressant benefit in a randomized clinical trial published in JAMA Network Open.
Home transcranial direct current stimulation paired with cognitive training delivered through a video game was feasible but offered no superior antidepressant benefit in a randomized clinical trial published in JAMA Network Open.
An individual participant data meta-analysis of 18 fixed-dose trials involving 7062 adults with acute schizophrenia found no evidence of sex differences in antipsychotic efficacy for overall symptom improvement.
An individual participant data meta-analysis of 18 fixed-dose trials involving 7062 adults with acute schizophrenia found no evidence of sex differences in antipsychotic efficacy for overall symptom improvement.
A connectivity-guided approach to accelerated iTBS produced greater short-term reductions in depression severity than conventional scalp-based targeting.
A connectivity-guided approach to accelerated iTBS produced greater short-term reductions in depression severity than conventional scalp-based targeting.
Young people beginning antipsychotic treatment after first-episode psychosis had low medication adherence, according to a retrospective US cohort study published in JAMA Network Open.
Young people beginning antipsychotic treatment after first-episode psychosis had low medication adherence, according to a retrospective US cohort study published in JAMA Network Open.
Reducing ultraprocessed food consumption was feasible and acceptable among adults with major depressive disorder (MDD) and was associated with lower depression and anxiety scores.
Reducing ultraprocessed food consumption was feasible and acceptable among adults with major depressive disorder (MDD) and was associated with lower depression and anxiety scores.
Vortioxetine was consistently associated with reduced depressive symptoms in older adults with MDD, while its effects on cognition were less consistent, according to a systematic review.
Vortioxetine was consistently associated with reduced depressive symptoms in older adults with MDD, while its effects on cognition were less consistent, according to a systematic review.
Semaglutide initiation was associated with fewer clinician-recorded cognitive signs and symptoms among adults with psychiatric disorders, according to a poster presented at Psych Congress.
Semaglutide initiation was associated with fewer clinician-recorded cognitive signs and symptoms among adults with psychiatric disorders, according to a poster presented at Psych Congress.
Two of the 5 characteristic symptoms of schizophrenia must be present for a diagnosis to be made. At least one of these must be which of the following, according to the DSM-5-TR? Take the quiz!
Two of the 5 characteristic symptoms of schizophrenia must be present for a diagnosis to be made. At least one of these must be which of the following, according to the DSM-5-TR? Take the quiz!
Which term refers to a psychotic symptom experienced with schizophrenia characterized by strong beliefs that are not true and may seem irrational to others? Take the quiz!
Which term refers to a psychotic symptom experienced with schizophrenia characterized by strong beliefs that are not true and may seem irrational to others? Take the quiz!
According to an interview with Rakesh Jain, MD, MPH, what is a common mistake clinicians make when evaluating sleep complaints in patients with psychiatric disorders?
According to an interview with Rakesh Jain, MD, MPH, what is a common mistake clinicians make when evaluating sleep complaints in patients with psychiatric disorders?
Arwen Podesta, MD, DFAPA, Psych Congress Steering Committee Member, and Mike Asbach, DMSc, PA-C, Co-Chair, Psych Congress PA Institute, discuss practical strategies for incorporating nutrition and exercise recommendations into psychiatric...
Arwen Podesta, MD, DFAPA, Psych Congress Steering Committee Member, and Mike Asbach, DMSc, PA-C, Co-Chair, Psych Congress PA Institute, discuss practical strategies for incorporating nutrition and exercise recommendations into psychiatric...
Kristian Dambrino, DNP, PMHNP-BC, explores the role that dual-mechanism and multimodal medications may play in individualized major depressive disorder (MDD) care.
Kristian Dambrino, DNP, PMHNP-BC, explores the role that dual-mechanism and multimodal medications may play in individualized major depressive disorder (MDD) care.
